[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581713":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":74,"collaborators":76,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":87,"minAge":88,"maxAge":23,"enrollmentInfo":89,"targetDuration":23,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":40,"whyStopped":23,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University Hospital, Limoges","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"HBV patient","a blood sample is done during a follow-up visit",[12],"Other: blood sample HBV patient",{"label":14,"type":6,"description":15,"interventionNames":16},"healthy volunteers","a blood sample",[17],"Other: blood sample healthy volunteers",[19,24],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"blood sample HBV patient","During a boold sample at only one follow up visit:\n\n* 3 tubes EDTA 10 ml per patient\n* 1 tube \"Paxgene\" 1ml\n* 2 dry tube per patient",[9],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"blood sample healthy volunteers","* 3 tubes EDTA ideally age and sex matched to CHB patient.\n* 1 tube \"Paxgene\" 1ml\n* 2 dry tube",[14],[29],{"name":30,"affiliation":5,"role":31},"Paul CARRIER, MD","PRINCIPAL_INVESTIGATOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":23,"email":36},"CONTACT","+335 55 05 80 22","paul.carrier@chu-limoges.fr",[38,54,62],{"facility":39,"status":40,"city":41,"state":23,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Centre d'Investigation Clinique","RECRUITING","Limoges","87042","France","FR",{"type":46,"coordinates":47},"Point",[48,49],1.24759,45.83362,{"lat":49,"lon":48},[52],{"name":53,"role":31,"phone":23,"phoneExt":23,"email":23},"Fabienne MARIAUD, MD",{"facility":55,"status":40,"city":41,"state":23,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"Limoges University Hospital",{"type":46,"coordinates":57},[48,49],{"lat":49,"lon":48},[60],{"name":61,"role":31,"phone":23,"phoneExt":23,"email":23},"Véronqiue LOUSTAUD-RATTI, MD",{"facility":63,"status":40,"city":64,"state":23,"zip":65,"country":43,"countryCode":44,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Hospice civils de Lyon","Lyon","69004",{"type":46,"coordinates":67},[68,69],4.84789,45.74906,{"lat":69,"lon":68},[72],{"name":73,"role":31,"phone":23,"phoneExt":23,"email":23},"Fabien ZOULIM, MD",{"type":75,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[77],{"name":78,"class":6},"National Agency for Research on AIDS and Viral Hepatitis (ANRS)","100581713","gene-discovery-in-chb-patients-to-identify-unknown-pathways-that-lead-to-b-and-nk-cell-deregulation-100581713",false,"NCT06853886","Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation","LiNKeB2","Inclusion Criteria:\n\n* Male or female, age ≥18 years old\n* HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog\n* Willing and able to provide written informed consent\n* Affiliated with a social securityregimen\n\nHealthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study:\n\n* Male or female, age between 18 and 80 years\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer)\n* Acute hepatitis in the year preceding recruitment\n* Other liver diseases : alcohol, obesity (BMI\\>30), diabetes, metabolic syndrome (dyslipidemia and\u002For known hypertension) - Underlying immunological or cancerous diseases\n* Patient with a disability that prevents him\u002Fher from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship\n* Pregnant or breast-feeding women.\n\nSecondary exclusion criteria:\n\n* A healthy volunteer whose vaccination status does not match that expected on the basis of serological results\n* Positive blood pregnancy test on inclusion\n* Positive HCV, HIV or HDV test in a patient\n* Positive HBV, HCV, HIV or HDV test in a healthy volunteer",true,"ALL","18 Years",{"count":90,"type":91},140,"ESTIMATED","INTERVENTIONAL",[94],"NA","Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.",[97],"Chronic Hepatitis B Virus",[99,100,101,102],"HBV","NK celles","TLR9","B cells","2026-05-19",{"date":105,"type":106},"2026-05-20","ACTUAL",{"date":108,"type":106},"2025-08-12",{"date":110,"type":91},"2028-10-01",{"name":5,"class":6},3]